Jeffrey I Zwicker1, Adam Rojan2, Federico Campigotto2, Nadia Rehman2, Renee Funches2, Gregory Connolly2, Jonathan Webster2, Anita Aggarwal2, Dalia Mobarek2, Charles Faselis2, Donna Neuberg2, Frederick R Rickles2, Ted Wun2, Michael B Streiff2, Alok A Khorana2. 1. Jeffrey I. Zwicker, Adam Rojan, and Renee Funches, Beth Israel Deaconess Medical Center and Harvard Medical School; Federico Campigotto and Donna Neuberg, Dana-Farber Cancer Institute, Boston, MA; Nadia Rehman and Ted Wun, University of California at Davis School of Medicine; Nadia Rehman and Ted Wun, VA Northern California Health Care System, Sacramento, CA; Gregory Connolly, University of Rochester Medical Center, Rochester, NY; Jonathan Webster and Michael B. Streiff, Johns Hopkins University School of Medicine, Baltimore, MD; Anita Aggarwal, Dalia Mobarek, Charles Faselis, and Frederick R. Rickles, Veterans Administration Medical Center and The George Washington University, Washington, DC; and Alok A. Khorana, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH. jzwicker@bidmc.harvard.edu. 2. Jeffrey I. Zwicker, Adam Rojan, and Renee Funches, Beth Israel Deaconess Medical Center and Harvard Medical School; Federico Campigotto and Donna Neuberg, Dana-Farber Cancer Institute, Boston, MA; Nadia Rehman and Ted Wun, University of California at Davis School of Medicine; Nadia Rehman and Ted Wun, VA Northern California Health Care System, Sacramento, CA; Gregory Connolly, University of Rochester Medical Center, Rochester, NY; Jonathan Webster and Michael B. Streiff, Johns Hopkins University School of Medicine, Baltimore, MD; Anita Aggarwal, Dalia Mobarek, Charles Faselis, and Frederick R. Rickles, Veterans Administration Medical Center and The George Washington University, Washington, DC; and Alok A. Khorana, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
Abstract
PURPOSE: Hospitalized patients with cancer are considered to be at high risk for venous thromboembolism (VTE). Despite strong recommendations in numerous clinical practice guidelines, retrospective studies have shown that pharmacologic thromboprophylaxis is underutilized in hospitalized patients with cancer. PATIENTS AND METHODS: We conducted a prospective, cross-sectional study of hospitalized patients with cancer at five academic hospitals to determine prescription rates of thromboprophylaxis and factors influencing its use during hospitalization. RESULTS: A total of 775 patients with cancer were enrolled across five academic medical centers. Two hundred forty-seven patients (31.9%) had relative contraindications to pharmacologic prophylaxis. Accounting for contraindications to anticoagulation, the overall rate of pharmacologic thromboprophylaxis was 74.2% (95% CI, 70.4% to 78.0%; 392 of 528 patients). Among the patients with cancer without contraindications for anticoagulation, individuals hospitalized with nonhematologic malignancies were significantly more likely to receive pharmacologic thromboprophylaxis than those with hematologic malignancies (odds ratio [OR], 2.34; 95% CI, 1.43 to 3.82; P=.007). Patients with cancer admitted for cancer therapy were significantly less likely to receive pharmacologic thromboprophylaxis than those admitted for other reasons (OR, 0.37; 95% CI, 0.22 to 0.61; P<.001). Sixty-three percent of patients with cancer classified as low risk, as determined by the Padua Scoring System, received anticoagulant thromboprophylaxis. Among the 136 patients who did not receive anticoagulation, 58.8% were considered to be high risk by the Padua Scoring System. CONCLUSION: We conclude that pharmacologic thromboprophylaxis is frequently administered to hospitalized patients with cancer but that nearly one third of patients are considered to have relative contraindications for prophylactic anticoagulation. Pharmacologic thromboprophylaxis in hospitalized patients with cancer is commonly prescribed without regard to the presence or absence of concomitant risk factors for VTE.
PURPOSE: Hospitalized patients with cancer are considered to be at high risk for venous thromboembolism (VTE). Despite strong recommendations in numerous clinical practice guidelines, retrospective studies have shown that pharmacologic thromboprophylaxis is underutilized in hospitalized patients with cancer. PATIENTS AND METHODS: We conducted a prospective, cross-sectional study of hospitalized patients with cancer at five academic hospitals to determine prescription rates of thromboprophylaxis and factors influencing its use during hospitalization. RESULTS: A total of 775 patients with cancer were enrolled across five academic medical centers. Two hundred forty-seven patients (31.9%) had relative contraindications to pharmacologic prophylaxis. Accounting for contraindications to anticoagulation, the overall rate of pharmacologic thromboprophylaxis was 74.2% (95% CI, 70.4% to 78.0%; 392 of 528 patients). Among the patients with cancer without contraindications for anticoagulation, individuals hospitalized with nonhematologic malignancies were significantly more likely to receive pharmacologic thromboprophylaxis than those with hematologic malignancies (odds ratio [OR], 2.34; 95% CI, 1.43 to 3.82; P=.007). Patients with cancer admitted for cancer therapy were significantly less likely to receive pharmacologic thromboprophylaxis than those admitted for other reasons (OR, 0.37; 95% CI, 0.22 to 0.61; P<.001). Sixty-three percent of patients with cancer classified as low risk, as determined by the Padua Scoring System, received anticoagulant thromboprophylaxis. Among the 136 patients who did not receive anticoagulation, 58.8% were considered to be high risk by the Padua Scoring System. CONCLUSION: We conclude that pharmacologic thromboprophylaxis is frequently administered to hospitalized patients with cancer but that nearly one third of patients are considered to have relative contraindications for prophylactic anticoagulation. Pharmacologic thromboprophylaxis in hospitalized patients with cancer is commonly prescribed without regard to the presence or absence of concomitant risk factors for VTE.
Authors: Hervé Decousus; Victor F Tapson; Jean-François Bergmann; Beng H Chong; James B Froehlich; Ajay K Kakkar; Geno J Merli; Manuel Monreal; Mashio Nakamura; Ricardo Pavanello; Mario Pini; Franco Piovella; Frederick A Spencer; Alex C Spyropoulos; Alexander G G Turpie; Rainer B Zotz; Gordon Fitzgerald; Frederick A Anderson Journal: Chest Date: 2010-05-07 Impact factor: 9.410
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni Journal: J Thromb Haemost Date: 2010-11 Impact factor: 5.824
Authors: Marc Carrier; Alok A Khorana; Patricia Moretto; Grégoire Le Gal; Rebecca Karp; Jeffrey I Zwicker Journal: Am J Med Date: 2013-10-05 Impact factor: 4.965
Authors: Alpesh N Amin; Helen Varker; Nicole Princic; Jay Lin; Stephen Thompson; Stephen Johnston Journal: J Hosp Med Date: 2011-12-21 Impact factor: 2.960
Authors: Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga Journal: J Clin Oncol Date: 2013-05-13 Impact factor: 44.544
Authors: Fan Ye; Carolyn Stalvey; Matheen A Khuddus; David E Winchester; Hale Z Toklu; Joseph J Mazza; Steven H Yale Journal: J Thromb Thrombolysis Date: 2017-07 Impact factor: 2.300
Authors: R Figueroa; A Alfonso; J López-Picazo; I Gil-Bazo; A García-Mouriz; J Hermida; J A Páramo; R Lecumberri Journal: Clin Transl Oncol Date: 2018-11-16 Impact factor: 3.405
Authors: Gabor Forgo; Evy Micieli; Walter Ageno; Lana A Castellucci; Gabriela Cesarman-Maus; Henry Ddungu; Erich Vinicius De Paula; Mert Dumantepe; Maria Cecilia Guillermo Esposito; Stavros V Konstantinides; Nils Kucher; Claire McLintock; Fionnuala Ní Áinle; Alex C Spyropoulos; Tetsumei Urano; Beverley J Hunt; Stefano Barco Journal: J Thromb Haemost Date: 2021-12-13 Impact factor: 16.036
Authors: Rocío Figueroa; Ana Alfonso; José López-Picazo; Ignacio Gil-Bazo; Alberto García-Mouriz; José Hermida; José Antonio Páramo; Ramón Lecumberri Journal: PLoS One Date: 2018-08-02 Impact factor: 3.240
Authors: Alok A Khorana; Nicole M Kuderer; Keith McCrae; Dejan Milentijevic; Guillaume Germain; François Laliberté; Sean D MacKnight; Patrick Lefebvre; Gary H Lyman; Michael B Streiff Journal: Cancer Med Date: 2020-09-20 Impact factor: 4.452